

MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

NCT06543082

| | |
|------------|------------------|
| Status | RECRUITING |
| Phase | Phase 4 |
| Sponsor | CHA University |
| Enrollment | 490 participants |

Key Eligibility Criteria

Inclusion (2)

- Participants with positive troponin acute coronary syndrome who have undergone implantation of ultrathin bioresorbable polymer sirolimus-eluting stents (Orsiro; Biotronik AG).
- Participants who have provided written informed consent.

Exclusion (16)

- Under 19 years of age.
- Stent treatment failure lesions (stent restenosis or thrombosis).
- Cardiac arrest or cardiogenic shock.
- Currently taking or requiring strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or P-glycoprotein inhibitors (cyclosporine, ranolazine).
- Presence of any of the following concomitant conditions: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia, severe gastrointestinal diseases, or genetic disorders such as galactose intolerance.

... and 11 more (see full listing online)

Locations (9 total)

CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, South Korea
Keimyung University Dongsan Hospital, Daegu, South Korea
Wonkwang University Hospital, Iksan, South Korea
... and 6 more locations